(kloe' ni deen).
» Clonidine contains not less than 99.0 percent and not more than 101.0 percent of C9H9N3Cl2, calculated on the dried basis.
Packaging and storage Preserve in tight containers, and store at room temperature.
USP Reference standards 11
USP Clonidine Related Compound A RS
B: Ultraviolet Absorption 197U
Solution: 0.3 mg per mL.
Medium: 0.01 N hydrochloric acid.
Absorptivities for the maxima at 271 and 279 should be about 2.1 and 1.8, calculated on the dried basis.
Appearance of solution
Color of solution Dissolve 1.0 g in 10.0 mL of methanol: the color of the solution is not more intense than 10 mL of a Standard solution containing 4.8 µg per mL of potassium chromate in water, when compared in matched color-comparison tubes (see Visual Comparison under Spectrophotometry and Light-Scattering 851).
Turbidity The test solution prepared as directed under Color of solution has no more turbidity than 10 mL of methanol, when compared in matched color-comparison tubes (see Visual Comparison under Spectrophotometry and Light-Scattering 851).
Loss on drying 731 Dry it under vacuum at 60 to constant weight: it loses not more than 0.5% of its weight.
Residue on ignition 281 Ignite at 500 ± 25 to constant weight: not more than 0.1%.
Heavy metals, Method II 231: 10 µg per g.
Solution A Dissolve 4 g of monobasic potassium phosphate in 1000 mL water. Adjust with 1 M phosphoric acid, prepared by diluting 115 g of phosphoric acid and diluting with water to 1000 mL, to a pH of 4.0.
Solution B Combine 750 mL of acetonitrile with 250 mL of Solution A.
Blank Solution A.
Mobile phase Use variable mixtures of Solution A and Solution B as directed for Chromatographic system (see System Suitability under Chromatography 621).
Acetylclonidine solution Dissolve about 1 mg of USP Clonidine Related Compound A RS in 1 mL of acetonitrile, and dilute with Solution A to 20 mL.
System suitability solution Combine an accurately weighed quantity of USP Clonidine RS and an appropriate volume of Acetylclonidine solution, and dissolve in and dilute with Solution A to obtain a solution containing about 0.86 mg per mL and 0.86 µg per mL, respectively.
Standard solution Dissolve an accurately weighed quantity of USP Clonidine RS in Solution A, and dilute quantitatively, and stepwise if necessary, with Solution A to obtain a solution having a known concentration of about 8.6 µg per mL.
Test solution Transfer about 43 mg of Clonidine, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Solution A to volume, and mix.
Chromatographic system (see Chromatography 621) The liquid chromatograph is equipped with 210-nm detector and a 3.0-mm × 15-cm column that contains 5-µm packing L56. The column temperature is maintained at 40. The flow rate is about 1.5 mL per minute. The chromatograph is programmed as follows.
Procedure Separately inject equal volumes (about 5 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the peak responses for all peaks not observed in the Blank. Calculate the percentage of each impurity in the Clonidine taken by the formula:
5(C/W)(ri / rS)in which C is the concentration, in µg per mL, of USP Clonidine RS in the Standard solution; W is the weight, in mg, of Clonidine used to prepare the Test solution; ri is the peak response for each impurity in the Test solution; and rS is the peak response of clonidine in the Standard solution: not more than 0.1% of any individual impurity is found; and not more than 0.2% of total impurities is found.
Assay Dissolve about 190 mg of Clonidine, accurately weighed, in about 100 mL of glacial acetic acid. Titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically, using a silversilver chloride glass combination electrode with liquid junction (see Titrimetry 541). Perform a blank determination, and make any necessary correction (see Titrimetry 541). Each mL of 0.1 N perchloric acid is equivalent to 23.01 mg of C9H9N3Cl2.
Auxiliary Information Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 2727Pharmacopeial Forum: Volume No. 29(1) Page 58